R170
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.420
- COAGULATION+0.420
- INFLAMMATORY_RESPONSE+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- HYPOXIA+0.380
- TNFA_SIGNALING_VIA_NFKB+0.380
- WNT_BETA_CATENIN_SIGNALING+0.350
- MYOGENESIS+0.310
- COMPLEMENT+0.290
Top 10 suppressed
- E2F_TARGETS-0.440
- G2M_CHECKPOINT-0.420
- MITOTIC_SPINDLE-0.390
- INTERFERON_ALPHA_RESPONSE-0.240
- PROTEIN_SECRETION-0.210
- UV_RESPONSE_DN-0.140
- MYC_TARGETS_V2-0.080
- SPERMATOGENESIS-0.080
- BILE_ACID_METABOLISM-0.060
- TGF_BETA_SIGNALING-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | b9189c77-004e-461a-9c15-b504b12a3030 | — | — | 0.867 |
| 2 | SRR1488349 | GTEX | — | 0.862 |
| 3 | TCGA-60-2720-01A-01R-0851-07 | — | cohortSQ1 | 0.843 |
| 4 | C3L-02963 | — | cohortSQ1 | 0.838 |
| 5 | AUR-AER6-TTM1-A-1-1-R-A742-41 | — | C | 0.837 |
| 6 | TCGA-21-5784-01A-01R-1635-07 | — | cohortSQ1 | 0.823 |
| 7 | TCGA-BH-A0HF-01A-11R-A056-07 | — | A | 0.822 |
| 8 | BS_FYRDYBMZ | high-grade glioma | — | 0.820 |
| 9 | SRR1465917 | GTEX | — | 0.818 |
| 10 | BS_8RHPJ740 | Ependymoma NOS | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.390 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| HYPOXIA | 0.380 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |